HK1213888A1 - 治療化合物和組合物以及其作為pkm2調節劑的用途 - Google Patents

治療化合物和組合物以及其作為pkm2調節劑的用途 Download PDF

Info

Publication number
HK1213888A1
HK1213888A1 HK16101847.5A HK16101847A HK1213888A1 HK 1213888 A1 HK1213888 A1 HK 1213888A1 HK 16101847 A HK16101847 A HK 16101847A HK 1213888 A1 HK1213888 A1 HK 1213888A1
Authority
HK
Hong Kong
Prior art keywords
compositions
therapeutic compounds
pkm2
modulators
pkm2 modulators
Prior art date
Application number
HK16101847.5A
Other languages
English (en)
Chinese (zh)
Inventor
．泊泊威次-馬勒
J.泊泊威次-马勒
．撒德斯
J.O.撒德斯
．扎勒
R.扎勒
．柴徹塔
G．柴彻塔
Original Assignee
安吉奥斯医药品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安吉奥斯医药品有限公司 filed Critical 安吉奥斯医药品有限公司
Publication of HK1213888A1 publication Critical patent/HK1213888A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16101847.5A 2012-11-08 2013-11-08 治療化合物和組合物以及其作為pkm2調節劑的用途 HK1213888A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261724266P 2012-11-08 2012-11-08
US61/724,266 2012-11-08
PCT/US2013/069193 WO2014074848A1 (en) 2012-11-08 2013-11-08 Therapeutic compounds and compositions and their use as pkm2 modulators

Publications (1)

Publication Number Publication Date
HK1213888A1 true HK1213888A1 (zh) 2016-07-15

Family

ID=49667584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101847.5A HK1213888A1 (zh) 2012-11-08 2013-11-08 治療化合物和組合物以及其作為pkm2調節劑的用途

Country Status (12)

Country Link
US (1) US9458132B2 (enExample)
EP (1) EP2917207A1 (enExample)
JP (1) JP6362610B2 (enExample)
KR (1) KR20150080619A (enExample)
CN (1) CN104822672B (enExample)
AU (1) AU2013342203B2 (enExample)
CA (1) CA2890664A1 (enExample)
EA (1) EA032007B1 (enExample)
HK (1) HK1213888A1 (enExample)
MX (1) MX2015005841A (enExample)
NZ (1) NZ707778A (enExample)
WO (1) WO2014074848A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062838A2 (en) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104817490B (zh) * 2015-05-13 2017-10-13 北京大学 氨基二硫代甲酸酯类化合物及其制备方法与应用
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
SG11202001262QA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
EP1797076A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP5632379B2 (ja) * 2008-10-09 2014-11-26 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2759547A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
CR20170071A (es) * 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
EP2448581B1 (en) * 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2797694A1 (en) * 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
EP2651898B1 (en) * 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
TWI549947B (zh) * 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
US9388164B2 (en) * 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
ME03074B (me) * 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji

Also Published As

Publication number Publication date
WO2014074848A1 (en) 2014-05-15
US20150307473A1 (en) 2015-10-29
JP6362610B2 (ja) 2018-07-25
AU2013342203B2 (en) 2017-11-23
EP2917207A1 (en) 2015-09-16
KR20150080619A (ko) 2015-07-09
CN104822672A (zh) 2015-08-05
MX2015005841A (es) 2016-01-08
NZ707778A (en) 2019-03-29
US9458132B2 (en) 2016-10-04
CA2890664A1 (en) 2014-05-15
AU2013342203A1 (en) 2015-05-21
JP2016501189A (ja) 2016-01-18
CN104822672B (zh) 2018-08-28
EA032007B1 (ru) 2019-03-29
EA201590881A1 (ru) 2015-08-31

Similar Documents

Publication Publication Date Title
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
HK1216175A1 (zh) 治療性化合物和組合物
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
PH12017501306A1 (en) Inhibitors of histone demethylases
CA2871471C (en) Dna-pk inhibitors
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
EP4450130A3 (en) Formulations of enzalutamide
IN2015DN01156A (enExample)
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12014502032A1 (en) Treatment of brain cancer
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
MX371343B (es) Moduladores del receptor x hepatico (lxr).
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof